G1/S cell cycle arrest provoked in human T cells by antibody to CD26

CD26 is T cell costimulatory molecule with dipeptidyl peptidase IV (DPPIV) enzyme activity located in its extracellular region. The expression of CD26 is enhanced after activation of T cells, while it is preferentially expressed on a subset of CD4+ memory T cells in the resting state. In this paper, we demonstrate that binding of the soluble anti‐CD26 monoclonal antibody (mAb) 1F7 inhibits human T‐cell growth and proliferation in both CD26‐transfected Jurkat T‐cell lines and human T‐cell clones by inducing G1/S arrest, which is associated with enhancement of p21Cip1 expression. This effect depends on the DPPIV enzyme activity of the CD26 molecule. Moreover, we show that expression of p21Cip1 after treatment with the anti‐CD26 mAb 1F7 appears to be induced through activation of extracellular signal‐regulated kinase (ERK) pathway. These data thus suggest that anti‐CD26 treatment may have potential use in the clinical setting involving activated T cell dysregulation, including autoimmune disorders and graft‐vs.‐host disease.

[1]  C. Morimoto,et al.  CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. Mills,et al.  In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  S. Pierce,et al.  Floating the raft hypothesis: lipid rafts play a role in immune cell activation. , 2001, Immunity.

[4]  B. Schraven,et al.  Adapters in lymphocyte signalling. , 2001, Current opinion in immunology.

[5]  P. Kourilsky,et al.  Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. , 2000, Immunity.

[6]  A. Khanna,et al.  In Vitro and In Vivo Transfection of p21 Gene Enhances Cyclosporin A-Mediated Inhibition of Lymphocyte Proliferation , 2000, The Journal of Immunology.

[7]  G. Dotto,et al.  p21(WAF1/Cip1): more than a break to the cell cycle? , 2000, Biochimica et biophysica acta.

[8]  J. Buolamwini.  Cell cycle molecular targets in novel anticancer drug discovery. , 2000, Current pharmaceutical design.

[9]  J. Johnston,et al.  Sustained activation of the raf-MEK-ERK pathway elicits cytokine unresponsiveness in T cells. , 1999, Journal of immunology.

[10]  P. W. Janes,et al.  Aggregation of Lipid Rafts Accompanies Signaling via the T Cell Antigen Receptor , 1999, The Journal of cell biology.

[11]  I. De Meester,et al.  CD26, let it cut or cut it down. , 1999, Immunology today.

[12]  S. Kornbluth,et al.  All aboard the cyclin train: subcellular trafficking of cyclins and their CDK partners. , 1999, Trends in cell biology.

[13]  Dominique Schols,et al.  Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV , 1998, The Journal of Biological Chemistry.

[14]  B. Fleischer,et al.  Dipeptidyl‐peptidase IV/CD26 on T cells: analysis of an alternative T‐cell activation pathway , 1998, Immunological reviews.

[15]  Chika Morimoto,et al.  The structure and function of CD26 in the T‐cell immune response , 1998, Immunological reviews.

[16]  M. Hegen,et al.  Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function. , 1998, Molecular immunology.

[17]  M. Ditto,et al.  Regulation of the Receptor Specificity and Function of the Chemokine RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) by Dipeptidyl Peptidase IV (CD26)-mediated Cleavage , 1997, The Journal of experimental medicine.

[18]  G. Freeman,et al.  Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. , 1997, Science.

[19]  A Sewing,et al.  High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.

[20]  H. Sabzevari,et al.  G1 arrest and high expression of cyclin kinase and apoptosis inhibitors in accumulated activated/memory phenotype CD4+ cells of older lupus mice , 1997, European journal of immunology.

[21]  M. Hegen,et al.  Cross‐linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen‐activated protein kinase , 1997, Immunology.

[22]  S. Nagataki,et al.  Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis. , 1996, The Journal of rheumatology.

[23]  C. Morimoto,et al.  Influence of CD26 and integrins on the antigen sensitivity of human memory T cells. , 1996, Human immunology.

[24]  S. Monfardini,et al.  The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. , 1995, Blood.

[25]  K. Umeki,et al.  CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma , 1995, International journal of cancer.

[26]  Xiao-Fan Wang,et al.  Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[28]  James M. Roberts,et al.  lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin , 1994, Nature.

[29]  G. Hannon,et al.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA , 1994, Nature.

[30]  Yi-Song Wang,et al.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. , 1994, Cancer research.

[31]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[32]  C. Morimoto,et al.  Direct association of adenosine deaminase with a T cell activation antigen, CD26. , 1993, Science.

[33]  H. Flad,et al.  Anti-CD26 monoclonal antibodies can reversibly arrest human T lymphocytes in the late G1 phase of the cell cycle. , 1993, Immunobiology.

[34]  G. Vanhoof,et al.  Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster. , 1993, Immunobiology.

[35]  C. Morimoto,et al.  The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Morimoto,et al.  CD27, a member of the nerve growth factor receptor family, is preferentially expressed on CD45RA+ CD4 T cell clones and involved in distinct immunoregulatory functions. , 1992, Journal of immunology.

[37]  B. Seed,et al.  Cloning and functional expression of the T cell activation antigen CD26. , 1992, Journal of immunology.

[38]  C. Morimoto,et al.  Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. , 1992, Molecular immunology.

[39]  C. Morimoto,et al.  Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. , 1991, Journal of immunology.

[40]  C. Morimoto,et al.  Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. , 1990, Journal of immunology.

[41]  N. Letvin,et al.  1F7, a novel cell surface molecule, involved in helper function of CD4 cells. , 1989, Journal of immunology.

[42]  K. Migita,et al.  Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease. , 1989, Journal of immunology.

[43]  E. Appella,et al.  Inhibition of T cell response with peptides is influenced by both peptide‐binding specificity of major histocompatibility complex molecules and susceptibility of T cells to blocking , 1989, European journal of immunology.

[44]  K. Meyer zum Büschenfelde,et al.  Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. , 1988, Clinical and experimental immunology.

[45]  N. Letvin,et al.  The isolation and characterization of the human helper inducer T cell subset. , 1985, Journal of immunology.

[46]  E. Reinherz,et al.  In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. , 1985, The New England journal of medicine.

[47]  F. Frassoni,et al.  Intravenous monoclonal antibody (BT 5/9) for the treatment of acute graft-versus-host disease. , 1985, Acta haematologica.

[48]  E. Reinherz,et al.  Monoclonal antibodies defining distinctive human T cell surface antigens. , 1979, Science.